Table 2. Clinicopathological and molecular characteristics of BRAF-mutant lesions.
| Total number | Proximal colon | Distal colon | Rectum | ||||
|---|---|---|---|---|---|---|---|
| Cecum | Ascending colon | Transverse colon | Descending colon | Sigmoid colon | |||
| Patients | 94 | 9 | 31 | 25 | 7 | 14 | 8 |
| Age (years, mean ± SD) | 62.9 ± 11.3 | 63.9 ± 8.3 | 65.8 ± 10.7 | 65.1 ± 12.9 | 60.3 ± 6.9 | 56.1 ± 12.4 | 65.0 ± 8.7 |
| Sex | |||||||
| Female | 36 (38.3%) | 5 | 13 | 15 | 1 | 2 | 0 |
| Male | 58 (61.7%) | 4 | 18 | 10 | 6 | 12 | 8 |
| Lesions | 106 | 9 | 37 | 28 | 7 | 17 | 8 |
| Morphology | |||||||
| Flat | 62 (58.5%) | 8 | 28 | 18 | 2 | 4 | 2 |
| Protruded | 41 (38.7%) | 1 | 8 | 9 | 5 | 13 | 5 |
| Flat+protruded | 3 (2.8%) | 1 | 1 | 1 | |||
| Size (mm, mean ± SD) | 10.2 ± 5.6 | 10.3 ± 5.8 | 11.7 ± 5.9 | 11.1 ± 5.8 | 7.7 ± 1.8 | 8.2 ± 4.9 | 6.5 ± 2.1 |
| Histology | |||||||
| HP/IM | 16 (15.1%) | 3 | 3 | 1 | 6 | 3 | |
| TSA | 15 (14.2%) | 1 | 1 | 2 | 8 | 3 | |
| TSA+SSA | 6 (5.7%) | 3 | 3 | ||||
| SSA | 49 (46.2%) | 9 | 20 | 14 | 3 | 2 | 1 |
| SSA+CD | 9 (8.5%) | 5 | 4 | ||||
| SSA+HGD | 7 (6.6%) | 3 | 3 | 1 | |||
| Conventional adenoma | 3 (2.8%) | 1 | 1 | 1 | |||
| HGD | 1 (0.9%) | 1 | |||||
| CIMP status | |||||||
| Positive | 57 (53.8%) | 5 | 27 | 18 | 4 | 2 | 1 |
| Negative | 49 (46.2%) | 4 | 10 | 10 | 3 | 15 | 7 |
| MLH1 methylation | |||||||
| Positive | 10 (12.9%) | 0 | 3 | 6 | 1 | 0 | 0 |
| Negative | 96 (87.1%) | 9 | 34 | 22 | 6 | 17 | 8 |
| Adjacent normal colon | 83 | 8 | 28 | 22 | 7 | 12 | 6 |
HP, hyperplastic polyp; IM, intermediate; TSA, traditional serrated adenoma; SSA, sessile serrated adenoma; CD, cytological dysplasia; HGD, high grade dysplasia